12-Month Lobbying Summary - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Registration Summary

Active - Last Updated: 2024-01-01

Who is lobbying?

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Mark Vineis, Country President

Responsible officer in previous versions
- Pedro Ferreira, Country President
- Andrea Marazzi, Country President

Received government funding or funding expected in current financial year

Business Relationships

Novartis Pharmaceuticals Canada Inc. is a subsidiary of the following parent companies

Novartis Holding AG (Address information)
Novartis Holding AG (Address information)

Beneficiaries of the Lobbying Activity

Novartis Pharmaceuticals Canada Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

What is being lobbied?

Subject Matters

Health
Industry
Intellectual Property
International Trade
Justice and Law Enforcement
Research and Development
Science and Technology

Subject Matter Details

Policies or Program

Canadian Agency for Drugs and Technologies in Health (CADTH), including Therapeutic Reviews and the Common Drug Review as it relates to reimbursement recommendations for decision-making process and framework.
Federal Innovation agenda. Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to ensure that innovative medicines, and our contribution to Research and Development in Canada are part of the consultation process in the development of this new innovation agenda.
Federal Public Drug Plans, with respect to the reimbursement of drug products for the Federal plan beneficiaries
Science and Technology Strategy, advocating for the development of a Biopharma sector in support of more research & development in Canada.
Working with our Industry Associations (Innovative Medicines Canada and BIOTECanada) to provide industry recommendations on Canada's Biomanufacturing and Life Sciences Strategy, National Pharmacare, Intellectual property as well as pricing reforms (PMPRB)

Policies or Program, Regulation

R&D requirements set forth through the Patent Medicines Pricing Review Board (PMPRB)

Regulation

Patent Medicines Pricing Review Board reforms, regarding both the revised regulations and draft guidelines
Patented Medicine Prices Review Board (PMPRB) Regulations as related to reporting requirements and pricing guidelines.
Patented Medicines (Notice of Compliance) Regulations as it relates to regulation of intellectual property for therapeutic products. Novartis is working with our industry associations (Innovative Medicines Canada and BIOTECanada) to provide a written response to Guideline consultation process and will provide our own corporate submission.

Who is being lobbied?

Government Institutions

Atlantic Canada Opportunities Agency (ACOA)
Canadian Heritage (PCH)
Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Indigenous Services Canada (ISC)
Innovation, Science and Economic Development Canada (ISED)
Natural Resources Canada (NRCan)
Pacific Economic Development Canada (PacifiCan)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Treasury Board Of Canada Secretariat (TBS)
Veterans Affairs Canada (VAC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

Written communication
Oral communication
Arrange one or more meetings

Who are the lobbyists?

Senior Officers whose lobbying activities represent less than 20% of their Duties

Mark Vineis, Country President | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Shona Kinley, Director, Public Affairs and Government Relations (Fed-Atlantic) | Public offices held

Registration number: 957165-15599
View all registrations versions

Monthly Communication Reports

What oral and arranged communications have taken place?

What oral and arranged communications have taken place?
Date	DPOH, Position Title \| Government Institution	Subject Matters
2024-02-29	Francesco Sorbara, Member of Parliment House of Commons	Industry, Health, Research and Development
2024-02-29	Rachel Blaney, Member of Parliament North Island Powell River House of Commons	Health, Research and Development
2024-02-29	Tom Kmiec, Member of Parliament, Calgary Shephard House of Commons	Industry, Science and Technology, Health
2023-12-07	Ritu Banerjee, Assistant Deputy Minister \| Director General's Office, Innovation, Science and Economic Development Canada (ISED)	Industry, Science and Technology, Health
2023-11-08	Ritu Banerjee, Assistant Deputy Minister \| Director General's Office, Innovation, Science and Economic Development Canada (ISED) Simon Kennedy, Sous-ministre Innovation, Science and Economic Development Canada (ISED)	Industry, Science and Technology, Health
2023-11-07	Jessica La Forge, Policy Advisor Pacific Economic Development Canada (PacifiCan) Gurjiven Sandhu, Director of Policy Pacific Economic Development Canada (PacifiCan)	Science and Technology, Health
2023-11-06	Stephen Ellis, Member of Parliament House of Commons	Health
2023-11-06	Chandra Arya, Member of Parliament House of Commons	Health
2023-11-06	Francesco Sorbara, Member of Parliment House of Commons	Industry, Health
2023-09-20	Christopher Johnstone, Assistant Deputy minister Health Canada (HC) Simon Kennedy, Sous-ministre Innovation, Science and Economic Development Canada (ISED) Darryl Patterson, Director General Innovation, Science and Economic Development Canada (ISED)	Industry, Science and Technology, Health, Research and Development
2023-08-17	Mark Holland, Minister of Health Health Canada (HC)	Science and Technology, Health
2023-06-23	Jocelyne Voisin, Assistant Deputy Minister Health Canada (HC)	Science and Technology, Health, Research and Development
2023-06-22	Jean-Sébastien Bock, Director of Policy \| Minister's Office, Health Canada (HC) Jean-Yves Duclos, Minister of Health Health Canada (HC) Sandenga Yeba, Senior Policy Advisor \| Minister's Office, Health Canada (HC)	Industry, Science and Technology, Health, Research and Development
2023-06-06	Andy Fillmore, Member of Parliament House of Commons	Industry, Science and Technology, Health

View all monthly communication reports

Novartis Pharmaceuticals Canada Inc. - Address & business activities

Address:

700 St-Hubert St., Suite 100
Montreal, QC H2Y 0C1
Canada

Telephone number: 514-631-6775

Contact information in previous versions
- 385 Bouchard Blvd.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 514-631-6775
- 385 Bouchard Blvd.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 877-631-6775
- 385 Bouchard Blvd.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 514-631-6775
- 385 Bouchard Blvd.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 514-631-9219
  
  Fax number: 514-717-9219
- 385 Bouchard Blvd.
  Dorval, QC H9S 1A9
  Canada
  
  Telephone number: 514-633-7880 Ext. 3395
  
  Fax number: 514-631-0307

Description of activities:
Marketing & distribution of pharmaceuticals products.

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Special Assistant Health Canada, Minister's Office	January 1996 to June 1996	Not a designated office

Date Modified:: 2024-04-04

Search and menus

Language selection

12-Month Lobbying Summary - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Who is lobbying?

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Novartis Pharmaceuticals Canada Inc. is a subsidiary of the following parent companies

Beneficiaries of the Lobbying Activity

What is being lobbied?

Subject Matters

Subject Matter Details

Policies or Program

Policies or Program, Regulation

Regulation

Who is being lobbied?

Government Institutions

Communication techniques

Who are the lobbyists?

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

What oral and arranged communications have taken place?

12-Month Lobbying Summary - In-house Corporation

Novartis Pharmaceuticals Canada Inc. / Mark Vineis, Country President

Novartis Pharmaceuticals Canada Inc. (Address & business activities)

Received government funding or funding expected in current financial year

Business Relationships

Novartis Pharmaceuticals Canada Inc. is a subsidiary of the following parent companies

Beneficiaries of the Lobbying Activity

Subject Matters

Subject Matter Details

Policies or Program

Policies or Program, Regulation

Regulation

Government Institutions

Communication techniques

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Novartis Pharmaceuticals Canada Inc. - Address & business activities

Novartis Holding AG

Novartis Holding AG